Our data revealed that caspases 3, and 9 were activated by Nar-Cpm combination, which is in line with the results of a previous study indicating that Nar causes dose-dependent increase in caspase-3 and caspase-9 activity in the breast cancer cells (1); However the activation of caspase 8 was not observed in our study. This evidence concerns the gene CASP3 and breast carcinoma.